APA (7th ed.) Citation

S, Z., I, B., J, C., LO, P., T, B., T, E., . . . MJ, S. (2026). Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: Results from a multi-institutional cohort (GUARDIANS). Cancer immunology, immunotherapy : CII, 75(7), . https://doi.org/10.1007/s00262-026-04448-2

Chicago Style (17th ed.) Citation

S, Zschäbitz, et al. "Effectiveness and Safety of Enfortumab Vedotin and Pembrolizumab in a Real-world Patient Population with Urothelial Carcinoma: Results from a Multi-institutional Cohort (GUARDIANS)." Cancer Immunology, Immunotherapy : CII 75, no. 7 (2026). https://doi.org/10.1007/s00262-026-04448-2.

MLA (9th ed.) Citation

S, Zschäbitz, et al. "Effectiveness and Safety of Enfortumab Vedotin and Pembrolizumab in a Real-world Patient Population with Urothelial Carcinoma: Results from a Multi-institutional Cohort (GUARDIANS)." Cancer Immunology, Immunotherapy : CII, vol. 75, no. 7, 2026, https://doi.org/10.1007/s00262-026-04448-2.